The use of infrared thermography for non-invasive detection of bleeding and musculoskeletal abnormalities in patients with hemophilia: an observational study.

"Declarations Ethics approval and consent to participateThe study was conducted after obtaining informed consent, and were approved by the Nara Medical University Ethics Committee and Chugai Ethics Committee. Consent for publicationNo identifiable subject information is provided in the manuscript, figures, and table. Competing interestsRK, AS, SH, ST, YN, NM, KT and MS: members of Medicinal Biology of Thrombosis and Hemostasis established by Nara Medical University and Chugai Pharmaceutical Co., Ltd.RK, SH, TS, YN, NM and YY: employees of Chugai Pharmaceutical Co., Ltd.RK, SH, NM and YY: stock ownership of Chugai Pharmaceutical Co., Ltd.TS, YN, YY and MS: Patents for inventions relating to products of Chugai Pharmaceutical Co., Ltd.AS: speaker’s bureau from CSL Behring.CH: no conflict of interest.KT: grants or research support from Japan Blood Products Organization, The Mother and Child Health Foundation and Novo Nordisk Pharma.KN: grants or research support from Chugai Pharmaceutical Co., Ltd., Takeda Pharmaceutical Co., Ltd., KM Biologics Co., Ltd., Sanofi, Novo Nordisk Pharma, Bayer and CSL Behring; honoraria or consultation fees from Chugai Pharmaceutical Co., Ltd., Takeda Pharmaceutical Co., Ltd., KM Biologics Co., Ltd., Sanofi, Novo Nordisk Pharma, Bayer and CSL Behring.MS: representative of Medicinal Biology of Thrombosis and Hemostasis collaborative research laboratory.; research support from Chugai Pharmaceutical Co., Ltd., Takeda Pharmaceutical Co., Ltd. and CSL Behring.; honoraria or consultation fees from Chugai Pharmaceutical Co., Ltd.; speaker’s bureau from Chugai Pharmaceutical Co., Ltd., CSL Behring, Sanofi, Bayer, Novo Nordisk Pharma, Takeda Pharmaceutical Co., Ltd., Pfizer and Fujimoto Seiyaku Corp. Competing interests RK, AS, SH, ST, YN, NM, KT and MS: members of Medicinal Biology of Thrombosis and Hemostasis established by Nara Medical University and Chugai Pharmaceutical Co., Ltd. RK, SH, TS, YN, NM and YY: employees of Chugai Pharmaceutical Co., Ltd. RK, SH, NM and YY: stock ownership of Chugai Pharmaceutical Co., Ltd. TS, YN, YY and MS: Patents for inventions relating to products of Chugai Pharmaceutical Co., Ltd. AS: speaker’s bureau from CSL Behring. CH: no conflict of interest. KT: grants or research support from Japan Blood Products Organization, The Mother and Child Health Foundation and Novo Nordisk Pharma. KN: grants or research support from Chugai Pharmaceutical Co., Ltd., Takeda Pharmaceutical Co., Ltd., KM Biologics Co., Ltd., Sanofi, Novo Nordisk Pharma, Bayer and CSL Behring; honoraria or consultation fees from Chugai Pharmaceutical Co., Ltd., Takeda Pharmaceutical Co., Ltd., KM Biologics Co., Ltd., Sanofi, Novo Nordisk Pharma, Bayer and CSL Behring. MS: representative of Medicinal Biology of Thrombosis and Hemostasis collaborative research laboratory.; research support from Chugai Pharmaceutical Co., Ltd., Takeda Pharmaceutical Co., Ltd. and CSL Behring.; honoraria or consultation fees from Chugai Pharmaceutical Co., Ltd.; speaker’s bureau from Chugai Pharmaceutical Co., Ltd., CSL Behring, Sanofi, Bayer, Novo Nordisk Pharma, Takeda Pharmaceutical Co., Ltd., Pfizer and Fujimoto Seiyaku Corp."

"Funding Chugai Pharmaceutical Co., Ltd."